63 results
8-K
EX-99.1
DYAI
Dyadic International Inc., DE
6 Oct 23
Other Events
4:20pm
, and a novel immune cell-based therapy for ALS and traumatic brain injury.
VIC explores and develops new ways to modulate the immune system for therapeutic
8-K
EX-10.1
DYAI
Dyadic International Inc., DE
12 Apr 23
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
8:30am
statutory requirements, and employers liability coverage per accident/disease/injury/general liability insurance, including contractual liability
8-K
EX-10.1
ftp8wwz7jm9 d7c
17 Dec 21
Dyadic Announces Research, License and Collaboration Agreement with Janssen
7:10am
8-K
EX-10.1
ka51j
9 Nov 21
Dyadic Appoints Chief Business Officer to Executive Leadership Team
8:40am
8-K
EX-10.1
ji57iyde
3 Jun 21
Entry into a Material Definitive Agreement
4:32pm
8-K
EX-10.1
cucmti
29 Jun 20
Entry into a Material Definitive Agreement
8:04am
8-K
EX-10.1
p099fweb
8 May 19
Dyadic Announces Sub-Licensing Agreement with Alphazyme
3:15pm
8-K
EX-10.1
b83y3az 5t58hcxts4xm
2 May 19
Dyadic Announces Sub-Licensing Agreement with Luina Bio
4:05pm
10-K
fc1 rqusfq6lx
27 Mar 19
Annual report
4:30pm
10-12G/A
9821hcs663v5zue 3kk8
8 Feb 19
Registration of securities (amended)
5:26pm
10-12G
EX-10.8
tpaipzmjm
14 Jan 19
Registration of securities
5:23pm
10-12G
EX-10.12
b9soh5 7aiosvet5r59
14 Jan 19
Registration of securities
5:23pm
10-12G
EX-10.6
3sx5n7fodi k42ynu
14 Jan 19
Registration of securities
5:23pm
10-12G
EX-10.5
ryz5lc5v1
14 Jan 19
Registration of securities
5:23pm